CCCC

C4 Therapeutics

Fundamental data last updated:March 2, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

66

Business Summary

C4 Therapeutics is a clinical-stage biopharmaceutical company focused on developing a new class of small-molecule drugs known as targeted protein degraders. These novel therapies are designed to identify and eliminate disease-causing proteins for the treatment of cancer and other diseases.

 


Analyze CCCC on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$262

Forward P/E

-

PEG

-

PRICE TO SALES

6.4

PRICE TO BOOK

1.7

EV / EBITDA

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$1.67

Next Year EPS Growth Estimate

-$1.29

Next Year Revenue Growth Estimate

-30.00%

Return on Equity (ROE)

-77.10%

FREE CASH FLOW

Operating Margin

-395.40%

Debt-to-Equity

0.4

Piotroski F-Score

Altman Z-Score

Return on Invested Capital (ROIC)

Current Ratio

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze CCCC on TradingView

Gainseekers Quantitative Analysis

Summary

C4 Therapeutics is a $262 million market cap biotechnology company with significant unprofitability, evidenced by an EPS of -$1.67 and an operating margin of -395.40%. The company faces a projected sales decline of -30.00% next year, yet maintains a high institutional ownership of 78.70%. Despite these challenges, analysts hold a strong consensus rating of 1.22.

AI Exposure / Tech Reliance

The provided data does not contain any information regarding the company's AI exposure or specific technology reliance.

The Bull Case

The bull case is supported by a strong analyst consensus rating of 1.22 and a mean consensus target price of $11.57. Additionally, institutional ownership is high at 78.70%, suggesting professional investor confidence.

The Bear Case

The company is deeply unprofitable, with a return on equity of -77.10% and an operating margin of -395.40%. Furthermore, sales are projected to decline by -30.00% next year.

Market Sentiment & Smart Money

Short Interest %

7.90%

Analyst Consensus

1.22

Average Analyst Price Target

$11.57

Institutional Ownership %

78.70%

1-Year Beta

Insider Buying % (6 Mo)

Distance to 52-Week High

Distance to 52-Week Low

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.